Adjuvant chemotherapy in males with cancer of the breast

C. S. Bagley, M. N. Wesley, R. C. Young, Marc E Lippman

Research output: Contribution to journalArticle

117 Citations (Scopus)

Abstract

Analysis of recurrence rates in male breast cancer (MBC) has suggested that tumor size and degree of axillary lymph node involvement carry the same prognostic implications as for breast cancer in women. A similar spectrum of antineoplastic agents appears active in both females and males. Based on reports of active adjuvant chemotherapy of women with breast cancer, we initiated a trial of adjuvant chemotherapy of MBC in July 1974. Twenty-four patients have been treated with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF). All patients had nodal involvement (median three nodes positive; seven patients had a single positive lymph node). All patients began adjuvant therapy within 4 weeks of either a radical or modified radical mastectomy. No postoperative radiotherapy was given. Median potential follow-up is 46 months. Four patients have recurred, one each at 15, 45, 61, and 65 months following mastectomy; two are dead of metastatic disease. The five-year survival rate projected by actuarial means is in excess of 80% (95% confidence interval: 74-100%). Based on these data, this treatment is highly encouraging when compared to other forms of treatment reported in the literature in which 5-year disease-free survival rates are less than 30%. We conclude that adjuvant therapy of MCB with a CMF regimen is feasible and may be associated with substantial improvement in disease-free survival and overall survival.

Original languageEnglish
Pages (from-to)55-60
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume10
Issue number1
StatePublished - Jan 1 1987
Externally publishedYes

Fingerprint

Male Breast Neoplasms
Adjuvant Chemotherapy
Methotrexate
Fluorouracil
Cyclophosphamide
Disease-Free Survival
Survival Rate
Lymph Nodes
Breast Neoplasms
Modified Radical Mastectomy
Mastectomy
Therapeutics
Antineoplastic Agents
Radiotherapy
Confidence Intervals
Recurrence
Survival
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bagley, C. S., Wesley, M. N., Young, R. C., & Lippman, M. E. (1987). Adjuvant chemotherapy in males with cancer of the breast. American Journal of Clinical Oncology: Cancer Clinical Trials, 10(1), 55-60.

Adjuvant chemotherapy in males with cancer of the breast. / Bagley, C. S.; Wesley, M. N.; Young, R. C.; Lippman, Marc E.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 10, No. 1, 01.01.1987, p. 55-60.

Research output: Contribution to journalArticle

Bagley, CS, Wesley, MN, Young, RC & Lippman, ME 1987, 'Adjuvant chemotherapy in males with cancer of the breast', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 10, no. 1, pp. 55-60.
Bagley, C. S. ; Wesley, M. N. ; Young, R. C. ; Lippman, Marc E. / Adjuvant chemotherapy in males with cancer of the breast. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1987 ; Vol. 10, No. 1. pp. 55-60.
@article{aa114928fc654d77ad1e2e6d24ef1cde,
title = "Adjuvant chemotherapy in males with cancer of the breast",
abstract = "Analysis of recurrence rates in male breast cancer (MBC) has suggested that tumor size and degree of axillary lymph node involvement carry the same prognostic implications as for breast cancer in women. A similar spectrum of antineoplastic agents appears active in both females and males. Based on reports of active adjuvant chemotherapy of women with breast cancer, we initiated a trial of adjuvant chemotherapy of MBC in July 1974. Twenty-four patients have been treated with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF). All patients had nodal involvement (median three nodes positive; seven patients had a single positive lymph node). All patients began adjuvant therapy within 4 weeks of either a radical or modified radical mastectomy. No postoperative radiotherapy was given. Median potential follow-up is 46 months. Four patients have recurred, one each at 15, 45, 61, and 65 months following mastectomy; two are dead of metastatic disease. The five-year survival rate projected by actuarial means is in excess of 80{\%} (95{\%} confidence interval: 74-100{\%}). Based on these data, this treatment is highly encouraging when compared to other forms of treatment reported in the literature in which 5-year disease-free survival rates are less than 30{\%}. We conclude that adjuvant therapy of MCB with a CMF regimen is feasible and may be associated with substantial improvement in disease-free survival and overall survival.",
author = "Bagley, {C. S.} and Wesley, {M. N.} and Young, {R. C.} and Lippman, {Marc E}",
year = "1987",
month = "1",
day = "1",
language = "English",
volume = "10",
pages = "55--60",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Adjuvant chemotherapy in males with cancer of the breast

AU - Bagley, C. S.

AU - Wesley, M. N.

AU - Young, R. C.

AU - Lippman, Marc E

PY - 1987/1/1

Y1 - 1987/1/1

N2 - Analysis of recurrence rates in male breast cancer (MBC) has suggested that tumor size and degree of axillary lymph node involvement carry the same prognostic implications as for breast cancer in women. A similar spectrum of antineoplastic agents appears active in both females and males. Based on reports of active adjuvant chemotherapy of women with breast cancer, we initiated a trial of adjuvant chemotherapy of MBC in July 1974. Twenty-four patients have been treated with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF). All patients had nodal involvement (median three nodes positive; seven patients had a single positive lymph node). All patients began adjuvant therapy within 4 weeks of either a radical or modified radical mastectomy. No postoperative radiotherapy was given. Median potential follow-up is 46 months. Four patients have recurred, one each at 15, 45, 61, and 65 months following mastectomy; two are dead of metastatic disease. The five-year survival rate projected by actuarial means is in excess of 80% (95% confidence interval: 74-100%). Based on these data, this treatment is highly encouraging when compared to other forms of treatment reported in the literature in which 5-year disease-free survival rates are less than 30%. We conclude that adjuvant therapy of MCB with a CMF regimen is feasible and may be associated with substantial improvement in disease-free survival and overall survival.

AB - Analysis of recurrence rates in male breast cancer (MBC) has suggested that tumor size and degree of axillary lymph node involvement carry the same prognostic implications as for breast cancer in women. A similar spectrum of antineoplastic agents appears active in both females and males. Based on reports of active adjuvant chemotherapy of women with breast cancer, we initiated a trial of adjuvant chemotherapy of MBC in July 1974. Twenty-four patients have been treated with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF). All patients had nodal involvement (median three nodes positive; seven patients had a single positive lymph node). All patients began adjuvant therapy within 4 weeks of either a radical or modified radical mastectomy. No postoperative radiotherapy was given. Median potential follow-up is 46 months. Four patients have recurred, one each at 15, 45, 61, and 65 months following mastectomy; two are dead of metastatic disease. The five-year survival rate projected by actuarial means is in excess of 80% (95% confidence interval: 74-100%). Based on these data, this treatment is highly encouraging when compared to other forms of treatment reported in the literature in which 5-year disease-free survival rates are less than 30%. We conclude that adjuvant therapy of MCB with a CMF regimen is feasible and may be associated with substantial improvement in disease-free survival and overall survival.

UR - http://www.scopus.com/inward/record.url?scp=0023149129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023149129&partnerID=8YFLogxK

M3 - Article

C2 - 3825994

AN - SCOPUS:0023149129

VL - 10

SP - 55

EP - 60

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 1

ER -